2025-10-23 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX) based on the data you provided, formatted as a report with numerical summaries and accompanying analysis:

## Recursion Pharmaceuticals (RXRX) Analysis

**Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging AI and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **Ticker:** RXRX
*   **Cumulative Return (RXRX):** -2.46%
*   **Cumulative Return (VOO):** 41.08%
*   **Absolute Divergence (Current):** -45.54%

**Divergence Analysis:**

*   **Max Divergence:** 84.1
*   **Min Divergence:** -64.3
*   **Relative Divergence:** 12.7

This indicates that RXRX has significantly underperformed the S&P 500 over the analyzed period. The relative divergence of 12.7 suggests that RXRX's performance is near the lower end of its historical divergence range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
| ---------- | ------ | ----- | ------- | ------ | ------ |
| 2021-2023 | 22.0%  | 81.0% | 26.0%   | -0.2   | 4.0    |
| 2022-2024 | 11.0%  | 81.0% | -10.0%  | 0.1   | 2.7    |
| 2023-2025 | 40.0%  | 80.0% | -24.0% | 0.1  | 2.5    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows variable performance across different periods, with the most recent period showing significant growth.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant volatility and risk.
*   **Alpha:** Alpha is inconsistent, suggesting that the company's performance is not consistently outperforming or underperforming its benchmark.
*   **Beta:** Beta values close to zero indicate a low correlation with the overall market, meaning the stock's movements are relatively independent of the S&P 500.
*   **Cap(B):** Market capitalization has been decreasing over the periods analyzed.

### 2. Recent Stock Price Fluctuations

*   **Current Price:** 6.11
*   **Last Market Data:** Price: 5.75, Previous Close: 6.11, Change: -5.89%
*   **5-Day Moving Average:** 6.36
*   **20-Day Moving Average:** 5.54
*   **60-Day Moving Average:** 5.25

**Analysis:** The recent price of 5.75 is below both the 5-day and 20-day moving averages, but above the 60-day moving average, suggesting a mixed trend. The significant negative change (-5.89%) in the last market indicates a sharp price decrease, which could be due to specific news or market sentiment.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 58.13
*   **PPO:** 1.44
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (195 shares - Very Safe - MRI:0.90) Monthly invest 1.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **20-Day Relative Divergence Change:** 3.6 (+) Short-term increase
*   **Expected Return:** -30.0%

**Analysis:**

*   **MRI:** A high MRI score (0.9) suggests a relatively favorable investment environment from a risk perspective.
*   **RSI:** The RSI of 58.13 is nearing overbought territory but is still within a neutral range.
*   **PPO:** The PPO is positive but near zero, suggesting recent price increase
*   **Hybrid Signal:**  Strong Buy signal.
*   **20-Day Relative Divergence Change:** The positive change indicates short-term positive momentum.
*   **Expected Return:** The negative expected return of -30.0% indicates that, based on the model, the stock is expected to underperform the S&P 500 in the long term (2+ years).

### 4. Recent News & Significant Events

*   **Meme Stock Association:** Jim Cramer's comment associating RXRX with meme stocks could introduce volatility.
*   **Earnings Anticipation:** The surge ahead of earnings suggests positive expectations.
*   **Positive Momentum:** Articles highlight recent price surges and potential for further gains.
*   **AI Partnerships & Acquisition:** New AI partnerships and acquisitions are driving positive sentiment.
*   **Market Growth:** A report projects significant growth in the AI in Biotechnology market.

**Analysis:** Recent news is overwhelmingly positive, focusing on AI partnerships, potential market growth, and recent price surges. However, the association with meme stocks introduces an element of speculative risk.

### 4-2. Analyst Opinions

*   **Consensus:** Hold (2.62 on a 1-5 scale)
*   **Target Price:** Average: 6.47, High: 10.00, Low: 3.00
*   **Rating Changes:** Not specified

**Analysis:** The consensus rating of "Hold" suggests that analysts are neutral on the stock. The wide range in target prices indicates uncertainty about the stock's future performance.

### 5. Recent Earnings Analysis

| 날짜         | EPS    | 매출      |
| ------------ | ------ | --------- |
| 2025-08-05 | -0.41  | 0.02 B$   |
| 2025-05-05 | -0.5   | 0.01 B$   |
| 2024-11-06 | -0.34  | 0.03 B$   |
| 2024-08-08 | -0.4   | 0.01 B$   |
| 2025-08-05 | -0.4   | 0.01 B$   |

**Analysis:** The company has consistently reported negative EPS, indicating losses. Revenue has been fluctuating, with the highest revenue reported on 2024-11-06.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| ---------- | ---------- | ------------- |
| 2025-06-30 | \$0.02B   | -5.54%        |
| 2025-03-31 | \$0.01B   | -47.31%       |
| 2024-12-31 | \$0.00B   | -183.62%      |
| 2024-09-30 | \$0.03B   | 53.69%        |
| 2024-06-30 | \$0.01B   | 36.14%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE       |
| ---------- | ---------- | --------- |
| 2025-06-30 | \$0.92B   | -18.70%   |
| 2025-03-31 | \$0.93B   | -21.68%   |
| 2024-12-31 | \$1.03B   | -17.29%   |
| 2024-09-30 | \$0.52B   | -18.27%   |
| 2024-06-30 | \$0.58B   | -16.69%   |

**Analysis:**

*   **Revenue & Profitability:** Revenue is inconsistent. Profit margins are mostly negative, except for two quarters in 2024.
*   **Capital & Profitability:** Equity has fluctuated. ROE has been consistently negative, indicating poor profitability relative to equity.

### 7. Overall Summary

Recursion Pharmaceuticals (RXRX) presents a mixed investment picture.

**Key Positives:**

*   **Strong Buy signal from Hybird Signal**
*   **AI Focus:** The company is positioned in a growing market (AI in biotechnology) and has formed strategic partnerships.
*   **Recent Momentum:** Recent news highlights positive price momentum and analyst optimism.
*   **High MRI :** relatively favorable investment environment from a risk perspective.

**Key Negatives:**

*   **Underperformance:** RXRX has significantly underperformed the S&P 500.
*   **Financials:** Consistent negative EPS and negative ROE indicate poor profitability.
*   **Volatility:** The association with meme stocks could increase volatility.
*   **Expected Return:** Negative expected return suggests potential underperformance against the S&P 500 in the long term.
*   **Analyst Sentiment:** Consensus rating of "Hold" indicates a neutral outlook from analysts.

**Conclusion:** RXRX is a high-risk, high-reward investment. Its success depends on its ability to capitalize on the growth of AI in biotechnology and improve its financial performance. The recent price surge and positive news may present short-term opportunities, but the long-term outlook is uncertain. The meme stock association and negative long-term return projection should be considered carefully.
